Overall rank by patents
#32,526
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Milestone Pharmaceuticals Inc.
USPTO PatentsView assignee record - 8 granted patents across 3 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
8
Total patents granted
3
CPC technology areas
11.3
Avg claims per patent
-86%
5-year filing velocity
The verdict
Milestone holds 8 US patents across 3 technology areas, rank #32,526 of 50,000 tracked assignees.
- #32,526
- of 50,000 US assignees by volume
- Top 93%
- by Innovation Score (20.5/100)
- 11.3
- avg claims per patent
- -86%
- filing velocity, last 5 yrs
Portfolio overview
Milestone Pharmaceuticals Inc. has been granted 8 US utility patents between 2016 and 2025, placing Milestone Pharmaceuticals Inc. at rank #32,526 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Milestone Pharmaceuticals Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Milestone sits between Microsemi Corp.—analog Mixed Signal Group Ltd. (8 patents, rank #32,522) and Miracor Medical Systems Gmbh (8 patents, rank #32,530) - the closest US assignees by grant volume. The composite Innovation Score of 20.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 7 in the 2015–2019 window, a -86% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Milestone Pharmaceuticals Inc.'s 11.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Milestone Pharmaceuticals Inc. against peers pursuing similar technology classes.
Who files at Milestone's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Microsemi —Analog…
Microsemi Corp.—Analog Mixed Signal Group Ltd.
8 patents
- Mid-america Machi…
Mid-America Machining, Inc.
8 patents
- Midnite Solar
Midnite Solar, Inc.
8 patents
- Midwest Concrete…
Midwest Concrete & Masonry Supply, Inc.
8 patents
- Milk Holding B V
Milk Holding B.V.
8 patents
- Mindskid Labs
Mindskid Labs, LLC
8 patents
- Minkasu
Minkasu, Inc
8 patents
- Miracor Medical S…
Miracor Medical Systems GmbH
8 patents
- Milestone Pharmac… ◀
Milestone Pharmaceuticals Inc.
8 patents
What this shows Milestone holds 8 patents at rank #32,526, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Milestone
By rank, the assignees closest to #32,526 in granted patent volume.
- Microsemi Corp.—analog Mixed Signal Group Ltd. #32,522 · 8 patents
- Mid-america Machining, Inc. #32,523 · 8 patents
- Midnite Solar, Inc. #32,524 · 8 patents
- Midwest Concrete & Masonry Supply, Inc. #32,525 · 8 patents
- Milk Holding B.v. #32,527 · 8 patents
- Mindskid Labs, Llc #32,528 · 8 patents
- Minkasu, Inc #32,529 · 8 patents
- Miracor Medical Systems Gmbh #32,530 · 8 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Milestone's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Milestone's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
20 Top 93% higher than 7% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 25.0% |
| 2017 | 1 | 12.5% |
| 2018 | 4 | 50.0% |
| 2025 | 1 | 12.5% |
Which technologies does Milestone Pharmaceuticals Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Velocity Declining
Frequently Asked Questions
How many patents does Milestone Pharmaceuticals Inc. hold?
Milestone Pharmaceuticals Inc. holds 8 US granted patents filed between 2016 and 2025, spanning 3 technology areas.
What is Milestone Pharmaceuticals Inc.'s Innovation Score?
Milestone Pharmaceuticals Inc. has an Innovation Score of 20.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Milestone Pharmaceuticals Inc. focus on?
Milestone Pharmaceuticals Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 8 patents. The company has filed patents in 3 CPC subclasses total.
Is Milestone Pharmaceuticals Inc.'s patent filing rate increasing or decreasing?
Milestone Pharmaceuticals Inc.'s recent filing velocity is -86% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Milestone Pharmaceuticals Inc.'s patents?
Milestone Pharmaceuticals Inc.'s patents average 11.3 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Milestone Pharmaceuticals Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Milestone's 8 grants land it in the top 93% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Milestone ranks #32,526 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.